Market Place
Sourcing Support
FDA Granted Priority Review to Dizal`s Sunvozertinib NDA
07 Jan 2025 //
PR NEWSWIRE
Dizal Shows Sunvozertinib Data For EGFR-Resistant Lung Cancer
11 Dec 2024 //
PR NEWSWIRE
Dizal`s Data on DZD8586 in B-cell Non-Hodgkin Lymphoma at ASH
09 Dec 2024 //
PR NEWSWIRE
Dizal Submits NDA for Sunvozertinib in EGFR Exon 20 NSCLC
08 Nov 2024 //
PR NEWSWIRE
Sunvozertinib Shows Efficacy In NSCLC With EGFR Exon 20 Mutations
16 Sep 2024 //
PR NEWSWIRE
Despite J&J`s Rybrevant full nod, FDA encourages Dizal to file for approval
26 Jun 2024 //
FIERCE PHARMA
Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL
20 Jun 2024 //
PR NEWSWIRE
Sunvozertinib`s EGFR20Ins NSCLC Study Meets Primary Endpoint
02 Jun 2024 //
PR NEWSWIRE
Dizal Sunvozertinib Egfr Exon 20: Biomarker Nsclc Mutation Treatment Analysis
24 May 2024 //
PR NEWSWIRE
Dizal`s Sunvozertinib EGFR20+ NSCLC Results at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the NSCLC
07 Apr 2024 //
PR NEWSWIRE
Dizal`s Sunvozertinib Pivotal Study Results Published in The Lancet Medicine
13 Dec 2023 //
PR NEWSWIRE
Dizal Impresses with Differentiated Hematological Oncology Portfolio at 2023 ASH
12 Dec 2023 //
PR NEWSWIRE
Dizal presents updated PhII PTLC data
12 Dec 2023 //
ENDPTS
ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med
11 Dec 2023 //
FIERCE BIOTECH
Dizal`s Golidocitinib Trial Demonstrates Durable Benefits for r/r PTCL
10 Dec 2023 //
PR NEWSWIRE
Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH
03 Nov 2023 //
BUSINESSWIRE
Sunvozertinib Showes Potential as a First-Line Treatment for EGFR Exon 20
23 Oct 2023 //
PR NEWSWIRE
Golidocitinib Granted Priority Review by NMPA for the Treatment of r/r PTCL
21 Sep 2023 //
PR NEWSWIRE
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib
14 Sep 2023 //
PR NEWSWIRE
Anova Partners with Dizal to Accelerate Development of DZD9008
06 Sep 2023 //
BUSINESSWIRE
Dizal`s Oncology Pipeline Continues to Impress with Presentations at 2023 ASCO
25 May 2023 //
PR NEWSWIRE
Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib
10 Jan 2023 //
PR NEWSWIRE
Dizal reports positive Phase I data for breast cancer therapy
06 Sep 2022 //
CLINICALTRIALSARENA
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study
05 Sep 2022 //
PRNEWSWIRE
Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 at 2022 ESMO
05 Sep 2022 //
PRNEWSWIRE
Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in NSCLC
05 Aug 2022 //
PRNEWSWIRE
Dizal to Demonstrate the Strength,Acceleration of its Portfolio at ASCO 2022
27 May 2022 //
PRNEWSWIRE
Dizal Announces New Data from the Phase I/II Study of Golidocitnib in r/r pTCL
13 May 2022 //
PRNEWSWIRE
Dizal Announces Pre-clinical and Clinical Results of Sunvozertinib
05 May 2022 //
PRNEWSWIRE
Dizal Pharma Receives FDA FTD for DZD4205 in r/r PTCL
18 Feb 2022 //
PRNEWSWIRE
